EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Histogen's enterprise value is $-3.08 Mil.
Histogen's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $0.02 Mil. Therefore, Histogen's EV-to-Revenue for today is -161.95.
The historical rank and industry rank for Histogen's EV-to-Revenue or its related term are showing as below:
HSTO'
s EV-to-Revenue Range Over the Past 10 Years
Min: -261.25 Med: -0.91 Max: 16.98
Current: -161.95
During the past 4 years, the highest EV-to-Revenue of Histogen was 16.98. The lowest was -261.25. And the median was -0.91.
HSTO's EV-to-Revenue is ranked better than 99.52% of 1033
companies
in the Biotechnology industry
Industry Median: 7.66
vs HSTO: -161.95
As of today (2024-04-28), Histogen's stock price is $0.351.
Histogen's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00. Therefore, Histogen's PS Ratio for today is 87.75.
Histogen EV-to-Revenue Historical Data
The historical data trend for Histogen's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Histogen's EV-to-Revenue
For the Biotechnology subindustry, Histogen's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Histogen's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Histogen's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Histogen's EV-to-Revenue falls into.
Histogen's current Enterprise Value is $-3.08 Mil.
Histogen's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Histogen's share price for today is $0.351.
Histogen's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Histogen EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Histogen's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HSTO has been successfully added to your 